Moran Wealth Management LLC Sells 2,538 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Moran Wealth Management LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 19,678 shares of the biopharmaceutical company’s stock after selling 2,538 shares during the quarter. Moran Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $14,017,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. CWA Asset Management Group LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth $298,000. Sigma Planning Corp increased its position in shares of Regeneron Pharmaceuticals by 4.1% during the third quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 16 shares during the period. Baker Avenue Asset Management LP bought a new position in Regeneron Pharmaceuticals in the third quarter worth about $707,000. Ashton Thomas Securities LLC lifted its holdings in Regeneron Pharmaceuticals by 10.5% in the third quarter. Ashton Thomas Securities LLC now owns 790 shares of the biopharmaceutical company’s stock worth $830,000 after buying an additional 75 shares during the period. Finally, Peregrine Asset Advisers Inc. bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $424,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on REGN shares. Robert W. Baird decreased their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Finally, TD Cowen dropped their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Up 1.3 %

REGN opened at $707.51 on Monday. The stock has a market capitalization of $77.35 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 2.34 and a beta of 0.27. The firm has a 50 day moving average price of $696.12 and a 200-day moving average price of $848.69. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $11.86 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.